Emosis

Menu
  • Emosis
  • Solution
    • Seeking a serial killer in patient’s blood
    • Induced diseases
    • Our answer: cells at center stage
    • Flow cytometry: the other colors of blood
  • Products
    • Hit Confirm®
    • ClotSeek®
    • Plateletogram®
    • OnkoClot®
    • Aplis®
  • About
    • Who we are
    • Our team
    • What drives us
    • Where we are
  • Investors
    • Well-balanced shareholding structure
    • A rich ecosystem
    • Market outlook
    • Regulatory
  • News
  • Contact us

Emosis

  • Emosis
  • Solution
    • Seeking a serial killer in patient’s blood
    • Induced diseases
    • Our answer: cells at center stage
    • Flow cytometry: the other colors of blood
  • Products
    • Hit Confirm®
    • ClotSeek®
    • Plateletogram®
    • OnkoClot®
    • Aplis®
  • About
    • Who we are
    • Our team
    • What drives us
    • Where we are
  • Investors
    • Well-balanced shareholding structure
    • A rich ecosystem
    • Market outlook
    • Regulatory
  • News
  • Contact us

 

left4 news

Emosis SAS and LeukoDx Ltd awarded Eurostars grant to develop ClotSeek a screening hypercoagulation test for point of care and critical care

  • Print
  • Email
Details
Published: 06 June 2017

Strasbourg, France and Jerusalem, Israel, June 6th, 2017

The French diagnostic company Emosis SAS and the Israeli firm LeukoDx Ltd signed a cooperation agreement to set-up and validate an assay cartridge for real time in-vitro diagnostic (IVD) of blood coagulation. The project, which will be completed within 2 years, represents a total budget of 1.5 million euros and will be partially subsidised by the Eurostars grant.

Download

Tweet

© 2021 Emosis Diagnostics

  • Sitemap

Website by e-novea web agency